Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016

Abstract

AbbVie. Plain language summary available for this article.

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

“…This benefit is especially relevant as the epidemiology of HCV infection is shifting towards a predominantly treatment-naïve population. 29 One limitation of this trial is the relatively low number of patients with HCV genotype 5 or 6 infection, despite no restrictions imposed on their enrollment. This reflects the relatively low prevalence of these genotypes in the regions where the trial was conducted.…”

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis

“…7 This is particularly important given the evolving epidemiology of HCV in some countries. The number of younger people with milder disease (fibrosis stage F0-F1) who are infected with HCV is increasing, 41 and the majority of new cases in these younger patients occur in those who use illicit injectable drugs. 41,42 The mITT SVR12 rate in patients with CKD stage 4-5 in this meta-analysis (99.0%) was also similar to that reported in a clinical study (100%).…”

“…The number of younger people with milder disease (fibrosis stage F0-F1) who are infected with HCV is increasing, 41 and the majority of new cases in these younger patients occur in those who use illicit injectable drugs. 41,42 The mITT SVR12 rate in patients with CKD stage 4-5 in this meta-analysis (99.0%) was also similar to that reported in a clinical study (100%). 8 The introduction of highly effective DAA therapies with short durations of treatment that can cure HCV infection has transformed the treatment landscape in recent years.…”

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

“…Treatment of hepatitis C significantly mitigates this economic burden from HCV/hepatic complications and extrahepatic manifestations [3]. However, only about 19% of the HCV ribonucleic acid (RNA)-positive patients were treated for HCV in the US in 2016 [4]. While eliminating HCV may be extremely challenging, the World Health Organization (WHO) and multiple public policy advocacy groups have established goals to eliminate HCV by 2030 [5].…”